Company overview
ProteoNic BioSciences offers proprietary vector technologies like 2G UNic™ to pharmaceutical, biotech, and CDMO companies for enhancing protein production, viral vector titers, and gene expression in mammalian, yeast, and fungal cells. The technology optimizes mRNA translation, boosts yields for complex proteins such as multi-specific antibodies, and lowers production costs through non-exclusive worldwide licensing. Validated across common expression platforms, it supports biologics and gene therapy manufacturing with customization options.
Spaceship.com is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, CDMO & Manufacturing partner serving United States & Americas. Core focus areas include proteonic, protein production, vector technology, 2g unic, biologics manufacturing.
Industry categories: Life Science Reagents, CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.proteonic.com/
- Categories
- Life Science Reagents, CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- proteonic, protein production, vector technology, 2g unic, biologics manufacturing
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What capabilities does ProteoNic offer for protein production?
- ProteoNic provides 2G UNic™ vector technology to boost transcription, translation, and yields for complex proteins in mammalian, yeast, and fungal cells, including viral vectors and multi-specific antibodies.
- What are the licensing terms and geographies?
- Licenses are non-exclusive and worldwide to pharmaceutical, biotech, and CDMO clients, with options for vectors, transfection-ready DNA, protocols, and custom variants.
- Is ProteoNic's technology validated and regulatory-ready?
- 2G UNic™ vectors are extensively validated in commercial mammalian platforms like CHO cells and available with expert support and protocols for manufacturing.
Related editorial coverage
- IPEC Excipient World Biologics Summit 2026: Recap
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
